Vitiligo Clinical Trials in Shanghai, Shanghai Municipality
3 recruitingShanghai, Shanghai Municipality, China
Showing 1–3 of 3 trials
Recruiting
Phase 1
Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration
HealthySevere Alopecia AreataActive Non-segmental Vitiligo
Innovent Biologics (Suzhou) Co. Ltd.160 enrolled1 locationNCT07554222
Recruiting
Phase 3
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
Vitiligo
Pfizer400 enrolled74 locationsNCT06163326
Recruiting
Not Applicable
Platelet-rich Plasma Intradermal Injection Combined With 308 nm Excimer Light for Treating Stable Acral Vitiligo
Vitiligo
Yijian Zhu20 enrolled1 locationNCT06394349